Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955377 | 1.00 | TSHR (0.38) | TSHRGAARAB9AACACBKDM4E | |
| SCHEMBL2775866 | 0.84 | RXFP1 (0.39) | TSHRGAAACACBHSD17B10L3MBTL1 | |
| SCHEMBL1968575 | 0.84 | RXFP1 (0.39) | TSHRGAAACACBHSD17B10L3MBTL1 | |
| SCHEMBL2830973 | 0.84 | ACACB (0.39) | TSHRGAAACACBKDM4EL3MBTL1 | |
| SCHEMBL7601775 | 0.82 | ALDH1A1 (0.39) | TSHRGAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL1967339 | 0.81 | KMT2A (0.41) | TSHRGAAACACBL3MBTL1KMT2A | |
| SCHEMBL1194168 | 0.79 | SOAT1 (0.41) | TSHRGAAKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL1564967 | 0.79 | SOAT1 (0.41) | TSHRGAAKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL8431191 | 0.79 | KMT2A (0.45) | TSHRGAAACACBL3MBTL1KMT2A | |
| SCHEMBL655102 | 0.77 | TSHR (0.43) | TSHRGAARAB9AACACBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | TSHR 147/4885GAA 4165/4885RAB9A 3231/4885 |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | GABBR1, GABBR2, GABRB1 | TSHR 114/4885GAA 922/4885RAB9A 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.